Ustekinumab and Upadacitinib for Induction and Maintenance Therapy in Patients With Refractory Crohn's Disease: A Multicenter, Randomized, Parallel-Controlled Study

"At Week 0:~≤55 kg: 260 mg administered by intravenous (IV) infusion.~\>55 kg and ≤85 kg: 390 mg administered by intravenous (IV) infusion.~\>85 kg: 520 mg administered by intravenous (IV) infusion.~From Week 8 onward (i.e., at Week 8 and then every 8 weeks up to Week 52 or the end of the follow-up period):~90 mg administered by subcutaneous (SC) injection."

"From Week 0 to Week 12: 45 mg once daily, administered orally.~From Week 13 through Week 52 or the end of the follow-up period: 30 mg once daily, administered orally."